DOCSLIB.ORG

Protein Kinase B/Akt at a Glance Elisabeth Fayard, Lionel A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Protein Kinase B/Akt at a Glance Elisabeth Fayard, Lionel A Cell Science at a Glance 5675 Protein kinase B/Akt at progression. Conserved from primitive This architecture is conserved among metazoans to humans, PKB belongs to the species from fly, worm, mouse to man. a glance AGC subfamily of the protein kinase Both the central kinase domain and the Elisabeth Fayard*, Lionel A. superfamily, which consists of 518 HM are highly conserved among AGC members in humans (Manning et al., members, such as protein kinase C, Tintignac*, Anne Baudry and 2002). PKB and v-AKT were first cloned ribosomal p90 S6 kinase, serum- and Brian A. Hemmings‡ in 1991 by three independent groups glucocorticoid-induced kinase, and p70 Friedrich Miescher Institute for Biomedical (Brazil and Hemmings, 2001), more than S6 kinase, mediators of responses Research, Maulbeerstrasse 66, 4058 Basel, Switzerland a decade after the original identification triggered by insulin and/or other growth *These authors contributed equally to this work of transforming murine leukemia virus factors. Interestingly, the PH domain, ‡Author for correspondence Akt8 (Staal et al., 1977). The PKB essential for binding to lipids such as (e-mail: [email protected]) subfamily comprises three mammalian PtdIns(3,4,5)P3, is absent in the S. ␣ ␤ ␥ Journal of Cell Science 118, 5675-5678 isoforms, PKB , PKB and PKB cerevisiae orthologue (Sch9). Published by The Company of Biologists 2005 (Akt1, Akt2 and Akt3, respectively), doi:10.1242/jcs.02724 which are products of distinct genes and share a conserved structure that includes PKB regulation Among the signalling proteins that three functional domains: an N-terminal The key role of PKB in signalling respond to a large variety of signals, pleckstrin homology (PH) domain, a became obvious when it was shown protein kinase B (PKB, also known as central kinase domain, and a C-terminal to be a downstream component Akt) appears to be a central player in regulatory domain containing the in phosphoinositide (PI) 3-kinase regulation of metabolism, cell survival, hydrophobic motif (HM) phosphorylation signalling, which is activated upon (1) motility, transcription and cell-cycle site [FxxF(S/T)Y] (Hanada et al., 2004). autophosphorylation of receptor tyrosine Protein Kinase B/Akt at a Glance Elisabeth Fayard, Lionel A. Tintignac, Anne Baudry and Brian A. Hemmings PKB-knockout mice PKB signalling in cancer Targeted isoform Survival Phenotype Cancer type Type of alteration PKBα/AKT1 GF PKBα/AKT2 Integrin GFR PKBα/AKT3 PTEN PKBα/AKT1 PKBβ/AKT2 SHIP P P wortmannin LY294002 PtdIns GPCR (4,5)P SHC 2 P P P P P P85 P110 (3 tdIn Grb2 ,4 s PtdIns P ,5) P CTMP P P P P (3,4,5)P Plasma membrane 3 PtdIns 3 Journal of Cell Science P ? (3,4,5)P TRB3 Paxillin SOS 3 P P P Keratin 10 P P Activity Identified S473 Activity FAK Ras T308 T308 x1000 upstream kinases PI3K x100 P P LY492002 PDK1 DNA-PK LY492002 Independent activation TORC2 i.e. stimulus-specific, LY492002 ATM cell-type-specific S473 S473 ␤ P PKC II Hsp90, Hsp27, MAPKAP-K2 PKB ternary structure Grb10, Ft1 PKB family phylogeny Angiogenesis Nematode 2 Nematode 1 eNOS Human 1 Caw Rat 1 Mouse 1 Chicken tion P Clawed frog a WNK1 loc Zebrafish s Human 2 n Rat 2 a P Tr IRS1 Mouse 2 Mouse 3 Rat 3 Human 3 6-PF2K Fruitfly Mosquito Metabolism PP2A n Inactivatio TSC2 PKB family structure Inactive e PH PHLPP as Thr-308Ser-473 P P GSK3 Kin PKB␣/Akt1 PH Kinase domain HM 480 HM Thr-309 Ser-474 IKK? BRF1 jcs.biologists.org P P FOXO1 ␤ Kinase domain T PKB /Akt2 PH HM Myt1 ra 481 n s Nuclear export Thr-305 Ser-472 PKB lo Mdm2 c P P a tio PLK1 PKB␥/Akt3 PH Kinase domain HM n ␬ ␣ ␬ 479 Raf I B NF- B Cytoplasm P P p21 p27* v-Akt Viral gag PH Kinase domain HM 755 Caspase 9* Cytoplasmic retention Nucleus Bad P Bax P NF-␬B Cell growth Symbol p53 Protein synthesis p27* Natural inhibitor of Inhibition of the target upon Transcription Mdm2 the PI3/PKB pathway PKB-mediated phosphorylation Mitochondria p21 Natural activator Activation of the target upon Cell survival FOXO4 FOXO3a of PKB PKB-mediated phosphorylation Degradation Phosphosite identified only in Chemical inhibitor the human protein Abbreviations: BAD, Bcl2 antagonist of cell death; BRF1, butyrate response factor 1; CTMP, C-terminal modulator protein; DNA PK, DNA-dependent protein kinase; eNOS, endothelial nitric oxide synthase; FAK, focal adhesion kinase; FOXO1, -3a, -4, Forkhead Box O1, -3a, -4 (FOXO1/FKHR, FOXO3a/FKHRL1 and FOXO4/AFX); Ft1, fused toes protein 1; GPCR, G-protein-coupled receptor; Grb, growth factor receptor bound protein; GSK3, glycogen synthase kinase 3; Hsp27, heat shock protein 27 kDa; Hsp90, heat shock protein 90 kDa; IKK, inhibitor of κ light chain enhancer in B cells; MAPKAP-K2, mitogen activated protein kinase activated protein kinase 2; Mdm2, mouse double minute 2; TORC2, TOR ␬ ␬ (target of rapamycin) complex 2; Myt1, membrane-associated and tyrosine/threonine-specific 1; NF- B, nuclear factor B; PDK1, 3-phosphoinositide-dependent protein kinase; PtdIns(4,5)P2, phosphatidylinositol (4,5)-bisphosphate; PtdIns(3,4,5)P3, phosphatidylinositol (3,4,5)-trisphosphate; PHLPP, PH domain and leucine-rich-repeat protein phosphatase; 6-PF2K, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase; PKC II, protein kinase C isoform beta 2; Plk1, Polo-like kinase1; PP2A, protein phosphatase 2 subunit A; Ras, rat sarcoma oncogene; SHC, Src homology 2 domain-containing transforming protein 1; SHIP, SH2-domain-containing inositol polyphosphate 5-phosphatase; SOS, Son of Sevenless. ©Journal of Cell Science 2005 (118, pp. 5675-5678) (See poster insert) 5676 Journal of Cell Science 118 (24) kinases induced by ligands (such as depend on the cellular and physiological isoforms still needs to be addressed, but insulin or other growth factors), (2) context. Phosphorylation of Ser473 is recent work on the three knockout mice stimulation of G-protein-coupled the key step in the activation of PKB suggests isoform-specific functions, as receptors, or (3) activation of integrin because it stabilizes the active well as some functional redundancy signalling (Foster et al., 2003; Wymann et conformation state (Yang et al., 2002). (Yang et al., 2004). al., 2003). PI 3-kinase is the key enzyme Once activated at the plasma membrane, in the generation of the second messenger phosphorylated PKB can translocate to Genetic manipulation of Pkb genes in PtdIns(3,4,5)P3 from PtdIns(4,5)P2. This the cytosol or the nucleus (Andjelkovic mice, either by transgenic or knockout allows the translocation of PKB from the et al., 1999). approaches, has brought novel insights cytoplasm to the plasma membrane, into PKB signalling (Brazil et al., 2004; which involves its PH domain. Interestingly, a number of PKB-binding Yang et al., 2004 and references therein). Interestingly, artificial targeting of PKB proteins have been shown to modulate These studies identified a wide range of to the plasma membrane, using a PKB activity further in either a positive in vivo functions of PKB, revealing myristoylated/palmitoylated sequence or negative manner. This suggests tissue-specific requirements for the motif fused to the N-terminus of PKB, transient regulation of the kinase by different PKB isoforms in metabolism induces constitutive activation of the adaptator proteins (Brazil et al., 2002; and embryonic development. Various kinase. Once recruited to the plasma Song et al., 2005). Moreover, several transgenic mice expressing membrane, PKB is activated by a multi- phosphatases negatively regulate PKB constitutively active PKB under the step process that requires phosphorylation activity. The tumor suppressor control of tissue-specific promoters have of both Thr308 in the activation loop of phosphatase and tensin homology been generated. From the analysis of the kinase domain and Ser473 within the deleted on chromosome ten (PTEN) these, it appears that PKB plays a major HM of the regulatory domain. (Stambolic et al., 1998) and role in cell growth: overexpression of Phosphorylation and subsequent the SH2-domain-containing inositol active PKB leads to cardiac or skeletal activation are prevented by the PI 3- polyphosphate 5-phosphatase (SHIP) muscle hypertrophy and an increase in kinase inhibitors wortmannin and (Huber et al., 1999) inhibit PKB activity ␤-cell mass and size, as well as LY294002, both of which are key indirectly by converting PtdIns(3,4,5)P3 potentially promoting the progression of diagnostic reagents for delineating to PtdIns(4,5)P2 and PtdIns(3,4)P2. tumours such as T cell lymphoma or signalling events associated with this Protein phosphatase 2A (PP2A) and PH prostate intraepithelial neoplasia (Lai et pathway. domain leucine-rich repeat protein al., 2004; Yang et al., 2004). phosphatase (PHLPP␣) do so directly by Interestingly, recent results from The serine/threonine kinase phospho- dephosphorylating Ser473 and/or transgenic mice expressing a kinase- inositide-dependent kinase 1 (PDK1), Thr308 on PKB (Andjelkovic et al., dead mutant of PKB␣ in ␤ cells suggest once recruited to the plasma membrane 1996; Gao et al., 2005). Although PKB that it is also involved in the regulation by PtdIns(3,4,5)P3 through its PH is also proposed to be activated in a PI of the insulin secretory pathway (Bernal- Journal of Cell Science domain, is the kinase responsible for the 3-kinase-independent manner Mizrachi et al., 2004). Expression of phosphorylation of Thr308 (Alessi et al., (Vanhaesebroeck and Alessi, 2000), the activated PKB␣ in the mammary gland 1997; Stephens et al., 1998). However, physiological significance of these results in delayed involution and the the identity of the Ser473 kinase findings requires further study. induction of lipid synthesis, leading to an (S473K, also called PDK2) is still increase in milk fat content and lactation controversial.
Load more

Recommended publications
  • Constitutive Activation of Akt/Protein Kinase B in Melanoma Leads to Up- Regulation of Nuclear Factor-␬B and Tumor Progression1
    [CANCER RESEARCH 62, 7335–7342, December 15, 2002] Constitutive Activation of Akt/Protein Kinase B in Melanoma Leads to Up- Regulation of Nuclear Factor-␬B and Tumor Progression1 Punita Dhawan, Amar B. Singh, Darrel L. Ellis, and Ann Richmond2 Departments of Veterans Affairs [A. R.], Cancer Biology [P. D., A. R.], Nephrology [A. B. S.], and Medicine, Division of Dermatology [D. L. E.], Vanderbilt University School of Medicine, Nashville, Tennessee 37232 ABSTRACT iting a cumulative melanoma risk of 1.9% compared with 0.04% of patients without dysplastic nevi (7). The current lifetime incidence The serine/threonine kinase Akt/protein kinase B and the pleiotropic of melanoma in the United States is estimated at 1:74 (8). The high transcription factor nuclear factor-␬B [NF-␬B (p50/p65)] play important incidence of dysplastic nevi and melanoma presents a large public roles in the control of cell proliferation, apoptosis, and oncogenesis. Pre- vious studies from our laboratory have shown the constitutive activation health problem. of NF-␬B in melanoma cells. However, the mechanism of this activation is Whereas histopathology is the current gold standard for the diag- not clearly understood. The purpose of this study was to explore the role nosis of atypical melanocytic lesions, interobserver correlation in the of Akt in the activation of NF-␬B during melanoma tumor progression. diagnosis of dysplastic nevi is variable (9, 10). The malignant poten- Based on our observation that two of the five melanoma cell lines exam- tial of dysplastic nevi and early melanomas is difficult to predict with ined exhibit constitutive Akt activation, we evaluated Akt activation by standard histological staining.
    [Show full text]
  • Supplementary Table 1. in Vitro Side Effect Profiling Study for LDN/OSU-0212320. Neurotransmitter Related Steroids
    Supplementary Table 1. In vitro side effect profiling study for LDN/OSU-0212320. Percent Inhibition Receptor 10 µM Neurotransmitter Related Adenosine, Non-selective 7.29% Adrenergic, Alpha 1, Non-selective 24.98% Adrenergic, Alpha 2, Non-selective 27.18% Adrenergic, Beta, Non-selective -20.94% Dopamine Transporter 8.69% Dopamine, D1 (h) 8.48% Dopamine, D2s (h) 4.06% GABA A, Agonist Site -16.15% GABA A, BDZ, alpha 1 site 12.73% GABA-B 13.60% Glutamate, AMPA Site (Ionotropic) 12.06% Glutamate, Kainate Site (Ionotropic) -1.03% Glutamate, NMDA Agonist Site (Ionotropic) 0.12% Glutamate, NMDA, Glycine (Stry-insens Site) 9.84% (Ionotropic) Glycine, Strychnine-sensitive 0.99% Histamine, H1 -5.54% Histamine, H2 16.54% Histamine, H3 4.80% Melatonin, Non-selective -5.54% Muscarinic, M1 (hr) -1.88% Muscarinic, M2 (h) 0.82% Muscarinic, Non-selective, Central 29.04% Muscarinic, Non-selective, Peripheral 0.29% Nicotinic, Neuronal (-BnTx insensitive) 7.85% Norepinephrine Transporter 2.87% Opioid, Non-selective -0.09% Opioid, Orphanin, ORL1 (h) 11.55% Serotonin Transporter -3.02% Serotonin, Non-selective 26.33% Sigma, Non-Selective 10.19% Steroids Estrogen 11.16% 1 Percent Inhibition Receptor 10 µM Testosterone (cytosolic) (h) 12.50% Ion Channels Calcium Channel, Type L (Dihydropyridine Site) 43.18% Calcium Channel, Type N 4.15% Potassium Channel, ATP-Sensitive -4.05% Potassium Channel, Ca2+ Act., VI 17.80% Potassium Channel, I(Kr) (hERG) (h) -6.44% Sodium, Site 2 -0.39% Second Messengers Nitric Oxide, NOS (Neuronal-Binding) -17.09% Prostaglandins Leukotriene,
    [Show full text]
  • Interaction Between the Protein Kinase B-Raf and the A-Subunit of the IIS Proteasome Regulator1
    (CANCER RESEARCH 58. 2986-2990, July 15, I998| Advances in Brief Interaction between the Protein Kinase B-Raf and the a-Subunit of the IIS Proteasome Regulator1 Andreas Kalmes,2 Garsten Hagemann,2 Christoph K. Weber, Ludmilla Wixler, Tillman Schuster, and Ulf R. Kapp* InstituífürMedizinische Strahlenkunde und Zettforschung (MSZ). University of Würzburg,97078 Würzburg,Germany ¡C.H.. C. K. W.. L. W.. T. S.. U. K. R.], and Department of Surgery, University of Washington, Seattle. Washington 9SI95 ¡A.KJ Abstract using the yeast two-hybrid system. In addition to the already known B-Raf-binding proteins (MEK and several 14-3-3 isoforms), we iso Protein kinases of the Raf family act as signal-transducing elements lated PA28a, the subunit of the 1IS proteasome regulator (11, 12), as downstream of activated cell surface receptors and are involved in the a novel B-Raf-binding partner. regulation of proliferation, differentiation, and cell survival. Whereas the role of c-Raf-1 as a mitogen-activated protein/extracellular signal-regu The 11S regulator is one of two known activators of the 20S lated kinase activator within the mitogenic cascade is well established, less proteasome (13). Both of these activators seem to possess different is known about the mammalian Raf isoforins A-Raf and B-Raf. Here we functions in vivo. The PA700 activator complex (19S regulator) binds report that B-Raf binds to PA28a, one of two subunits of the 1IS regulator to the 20S proteasome core complex to form the active 26S protea of proteasomes. PA28<* was isolated as a B-Raf-binding protein in a yeast some, which mediates the ATP- and ubiquitination-dependent degra two-hybrid screen of a PC 12 cDNA library.
    [Show full text]
  • Dynamic Modelling of the Mtor Signalling Network Reveals Complex
    www.nature.com/scientificreports OPEN Dynamic modelling of the mTOR signalling network reveals complex emergent behaviours conferred by Received: 24 August 2017 Accepted: 1 December 2017 DEPTOR Published: xx xx xxxx Thawfeek M. Varusai1,4 & Lan K. Nguyen2,3,4 The mechanistic Target of Rapamycin (mTOR) signalling network is an evolutionarily conserved network that controls key cellular processes, including cell growth and metabolism. Consisting of the major kinase complexes mTOR Complex 1 and 2 (mTORC1/2), the mTOR network harbours complex interactions and feedback loops. The DEP domain-containing mTOR-interacting protein (DEPTOR) was recently identifed as an endogenous inhibitor of both mTORC1 and 2 through direct interactions, and is in turn degraded by mTORC1/2, adding an extra layer of complexity to the mTOR network. Yet, the dynamic properties of the DEPTOR-mTOR network and the roles of DEPTOR in coordinating mTORC1/2 activation dynamics have not been characterised. Using computational modelling, systems analysis and dynamic simulations we show that DEPTOR confers remarkably rich and complex dynamic behaviours to mTOR signalling, including abrupt, bistable switches, oscillations and co-existing bistable/oscillatory responses. Transitions between these distinct modes of behaviour are enabled by modulating DEPTOR expression alone. We characterise the governing conditions for the observed dynamics by elucidating the network in its vast multi-dimensional parameter space, and develop strategies to identify core network design motifs underlying these dynamics. Our fndings provide new systems-level insights into the complexity of mTOR signalling contributed by DEPTOR. Discovered in the early 1990s as an anti-fungal agent produced by the soil bacterium Streptomyces hygroscopicus, rapamycin has continually surprised scientists with its diverse clinical efects including potent immunosuppres- sive and anti-tumorigenic properties1–3.
    [Show full text]
  • Iκb Kinase Ε and TANK-Binding Kinase 1 Activate AKT by Direct Phosphorylation
    IκB kinase ε and TANK-binding kinase 1 activate AKT by direct phosphorylation Xiaoduo Xiea, Denghong Zhangb, Bin Zhaoa, Min-Kan Lua, Ming Youc, Gianluigi Condorellib, Cun-Yu Wangd, and Kun-Liang Guana,1 aDepartment of Pharmacology and Moores Cancer Center and bDepartment of Medicine, University of California at San Diego, La Jolla, CA 92093; cCancer Center, Medical College of Wisconsin, Milwaukee, WI 53226; and dLaboratory of Molecular Signaling, Division of Oral Biology and Medicine, University of California Los Angeles School of Dentistry, Los Angeles, CA 90095 Edited* by Jack E. Dixon, The Howard Hughes Medical Institute, Chevy Chase, MD, and approved March 8, 2011 (received for review October 27, 2010) AKT activation requires phosphorylation of the activation loop The noncanonical IκB kinase ε (IKKε) has been demonstrated (T308) by 3-phosphoinositide-dependent protein kinase 1 (PDK1) to play an essential role in Ras-induced cell transformation, which and the hydrophobic motif (S473) by the mammalian target of requires activation of both the Raf-MEK-ERK and PI3K-AKT rapamycin complex 2 (mTORC2). We recently observed that pathways (20). Of particular interest is the observation that IKKε phosphorylation of the AKT hydrophobic motif was dramatically can functionally replace the requirement of AKT to support cell elevated, rather than decreased, in mTOR knockout heart tissues, transformation, which suggests that IKKε may act as an AKT indicating the existence of other kinase(s) contributing to AKT regulator or effector. Consistently, IKKε was found to be ampli- phosphorylation. Here we show that the atypical IκB kinase ε and fied in several types of human cancer, including ovarian cancer TANK-binding kinase 1 (IKKε/TBK1) phosphorylate AKT on both the and breast cancer (20, 21).
    [Show full text]
  • Kinase Signaling Cascades in the Mitochondrion: a Matter of Life Or Death$
    Free Radical Biology & Medicine 38 (2005) 2–11 www.elsevier.com/locate/freeradbiomed Serial Review: The powerhouse takes control of the cell: The role of mitochondria in signal transduction Serial Review Editor: Victor Darley-Usmar Kinase signaling cascades in the mitochondrion: a matter of life or death$ Craig Horbinski, Charleen T. Chu* Division of Neuropathology, Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA Received 15 July 2004; accepted 22 September 2004 Available online 27 October 2004 Abstract In addition to powering energy needs of the cell, mitochondria function as pivotal integrators of cell survival/death signals. In recent years, numerous studies indicate that each of the major kinase signaling pathways can be stimulated to target the mitochondrion. These include protein kinase A, protein kinase B/Akt, protein kinase C, extracellular signal-regulated protein kinase, c-Jun N-terminal kinase, and p38 mitogen- activated protein kinase. Although most studies focus on phosphorylation of pro- and antiapoptotic proteins (BAD, Bax, Bcl-2, Bcl-xL), kinase- mediated regulation of complex I activity, anion and cation channels, metabolic enzymes, and Mn-SOD mRNA has also been reported. Recent identification of a number of scaffold proteins (AKAP, PICK, Sab) that bring specific kinases to the cytoplasmic surface of mitochondria further emphasizes the importance of mitochondrial kinase signaling. Immunogold electron microscopy, subcellular fractionation, and immuno- fluorescence studies demonstrate the presence of kinases within subcompartments of the mitochondrion, following diverse stimuli and in neurodegenerative diseases. Given the sensitivity of these signaling pathways to reactive oxygen and nitrogen species, in situ activation of mitochondrial kinases may represent a potent reverse-signaling mechanism for communication of mitochondrial status to the rest of the cell.
    [Show full text]
  • Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle Svetlana E
    Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle Svetlana E. Nikoulina,1,2 Theodore P. Ciaraldi,1,2 Sunder Mudaliar,1,2 Leslie Carter,1,2 Kirk Johnson,3 and Robert R. Henry1,2 Glycogen synthase kinase (GSK)-3 has been implicated on insulin action, using mechanisms that differ from and in the regulation of multiple cellular physiological pro- are additive to those of insulin. Diabetes 51:2190–2198, cesses in skeletal muscle. Selective cell-permeable re- 2002 versible inhibitors (INHs) of GSK-3 (CT98014 and CHIR98023 [Chiron, Emeryville, CA] and LiCl) were used to evaluate the role of GSK-3 in controlling glucose metabolism. Acute treatment (30 min) of cultured hu- lycogen synthase kinase (GSK)-3 is a serine/ man skeletal muscle cells with either INH resulted in a threonine kinase originally discovered because dose-dependent activation of glycogen synthase (GS) of its ability to phosphorylate and inhibit gly- ϳ ␮ with a maximally effective concentration of 2 mol/l. cogen synthase (GS) (1). Human GSK-3 exists The maximal acute effect of either INH on GS (103 ؎ G as two isoforms, ␣ and ␤, encoded by two distinct genes, 25% stimulation over basal) was greater than the max- -imal insulin response (48 ؎ 9%, P < 0.05 vs. INH); LiCl located on chromosomes 19q13.1-2 and 3q13.3-q21, respec was as effective as insulin. The GSK-3 inhibitor effect, tively (2). GSK-3 is constitutively active in resting cells and like that of insulin, was on the activation state (frac- is inhibited by several hormones such as insulin, endothe- tional velocity [FV]) of GS.
    [Show full text]
  • The Role of GSK-3 in the Regulation of Protein Turnover, Myosin
    International Journal of Molecular Sciences Review The Role of GSK-3β in the Regulation of Protein Turnover, Myosin Phenotype, and Oxidative Capacity in Skeletal Muscle under Disuse Conditions Timur M. Mirzoev * , Kristina A. Sharlo and Boris S. Shenkman Myology Laboratory, Institute of Biomedical Problems RAS, 123007 Moscow, Russia; [email protected] (K.A.S.); [email protected] (B.S.S.) * Correspondence: [email protected] Abstract: Skeletal muscles, being one of the most abundant tissues in the body, are involved in many vital processes, such as locomotion, posture maintenance, respiration, glucose homeostasis, etc. Hence, the maintenance of skeletal muscle mass is crucial for overall health, prevention of various diseases, and contributes to an individual’s quality of life. Prolonged muscle inactivity/disuse (due to limb immobilization, mechanical ventilation, bedrest, spaceflight) represents one of the typical causes, leading to the loss of muscle mass and function. This disuse-induced muscle loss primarily results from repressed protein synthesis and increased proteolysis. Further, prolonged disuse results in slow-to-fast fiber-type transition, mitochondrial dysfunction and reduced oxidative capacity. Glycogen synthase kinase 3β (GSK-3β) is a key enzyme standing at the crossroads of various signaling pathways regulating a wide range of cellular processes. This review discusses various important roles of GSK-3β in the regulation of protein turnover, myosin phenotype, and oxidative capacity in skeletal muscles under disuse/unloading conditions and subsequent recovery. According Citation: Mirzoev, T.M.; Sharlo, K.A.; to its vital functions, GSK-3β may represent a perspective therapeutic target in the treatment of Shenkman, B.S. The Role of GSK-3β muscle wasting induced by chronic disuse, aging, and a number of diseases.
    [Show full text]
  • The Serine/Threonine Protein Kinase (Akt)/ Protein Kinase B (Pkb) Signaling Pathway in Breast Cancer
    Journal of Mind and Medical Sciences Volume 7 Issue 1 Article 7 2020 The Serine/Threonine Protein Kinase (Akt)/ Protein Kinase B (PkB) Signaling Pathway in Breast Cancer Daniela Miricescu FACULTY OF DENTAL MEDICINE, DEPARTMENT OF BIOCHEMISTRY, BUCHAREST, ROMANIA Camelia Cristina Diaconu CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, CLINICAL EMERGENCY HOSPITAL OF BUCHAREST, INTERNAL MEDICINE CLINIC, BUCHAREST, ROMANIA Constantin Stefani CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, DEPARTMENT OF FAMILY MEDICINE, BUCHAREST, ROMANIA Ana Maria Alexandra Stanescu CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY, DEPARTMENT OF FAMILY MEDICINE, BUCHAREST, ROMANIA Alexandra Totan FAollowCULT thisY OF and DEN additionalTAL MEDICINE, works at:DEP https:/ARTMEN/scholarT OF.v BIOCHEMISTRalpo.edu/jmmsY, BUCHAREST, ROMANIA Part of the Obstetrics and Gynecology Commons, Oncology Commons, and the Palliative Care SeeCommons next page for additional authors Recommended Citation Miricescu, Daniela; Diaconu, Camelia Cristina; Stefani, Constantin; Stanescu, Ana Maria Alexandra; Totan, Alexandra; Rusu, Ioana Ruxandra; Bratu, Ovidiu Gabriel; Spinu, Dan; and Greabu, Maria (2020) "The Serine/ Threonine Protein Kinase (Akt)/ Protein Kinase B (PkB) Signaling Pathway in Breast Cancer," Journal of Mind and Medical Sciences: Vol. 7 : Iss. 1 , Article 7. DOI: 10.22543/7674.71.P3439 Available at: https://scholar.valpo.edu/jmms/vol7/iss1/7 This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal
    [Show full text]
  • Guilty As Charged: B-RAF Is a Human Oncogene
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector REVIEW Guilty as charged: B-RAF is a human oncogene Mathew J. Garnett1 and Richard Marais1,* 1Signal Transduction Team, Cancer Research UK Centre for Cell and Molecular Biology, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, United Kingdom *Correspondence: [email protected] RAF proteins are components of a conserved signaling pathway that regulates cellular responses to extracellular signals. Despite over 20 years of research into the regulation and function of the RAF proteins, it was only realized recently that the B- RAF isoform is mutated at a high frequency in human cancer. Here we review the rapid progress made in our understanding of B-RAF as an oncogene and of its role in cancer. Introduction and activation segment phosphorylation, but in addition, they There are three RAF paralogs in humans: A-RAF, B-RAF, and require N region phosphorylation. C-RAF (also called Raf-1) (Marais and Marshall, 1996). These serine/threonine protein kinases are components of a con- The A to Z of B-RAF mutations served signaling pathway downstream of the membrane-bound The highest incidence of B-RAF mutations is in malignant small G protein RAS, which is activated by growth factors, hor- melanoma (27%–70%), papillary thyroid cancer (36%–53%), mones, and cytokines (Robinson and Cobb, 1997). RAS stimu- colorectal cancer (5%–22%), and serous ovarian cancer lates RAF activation, which then activates a second protein (?30%), but they also occur at a low frequency (1%–3%) in a kinase called MEK, which in turn activates a third protein kinase wide variety of other cancers (Table 1).
    [Show full text]
  • Mouse Anti-Human BRAF V600E Monoclonal Antibody, Clone JID711 (CABT-L2810) This Product Is for Research Use Only and Is Not Intended for Diagnostic Use
    Mouse Anti-Human BRAF V600E monoclonal antibody, clone JID711 (CABT-L2810) This product is for research use only and is not intended for diagnostic use. PRODUCT INFORMATION Product Overview This antibody is intended for qualified laboratories to qualitatively identify by light microscopy the presence of associated antigens in sections of formalin-fixed, paraffin-embedded tissue sections using IHC test methods. Specificity Human BRAF V600E Isotype IgG Source/Host Mouse Species Reactivity Human Clone JID711 Conjugate Unconjugated Applications IHC Reconstitution The prediluted antibody does not require any mixing, dilution, reconstitution, or titration; the antibody is ready-to-use and optimized for staining. The concentrated antibody requires dilution in the optimized buffer, to the recommended working dilution range. Positive Control Colorectal Adenocarcinoma, Thyroid Papillary Carcinoma with the BRAF V600E Mutation Format Liquid Size Predilut: 7ml; Concentrate: 100ul, 1ml. Positive control slides also available. Buffer Predilute: Antibody Diluent Buffer Concentrate: Tris Buffer, pH 7.3 - 7.7, with 1% BSA Preservative <0.1% Sodium Azide Storage Store at 2-8°C. Do not freeze. Ship Wet ice 45-1 Ramsey Road, Shirley, NY 11967, USA Email: [email protected] Tel: 1-631-624-4882 Fax: 1-631-938-8221 1 © Creative Diagnostics All Rights Reserved Warnings This antibody is intended for use in Immunohistochemical applications on formalinfixed paraffin- embedded tissues (FFPE), frozen tissue sections and cell preparations. BACKGROUND Introduction Serine/threonine-protein kinase B-Raf (BRAF) is a cytoplasmic serine-threonine kinase of the RAF family which mediates downstream cellular responses to growth signals through the mitogen-activated protein kinase (MAPK) signaling pathway.
    [Show full text]
  • Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma
    cancers Article Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance 1, , 2, 1 3 Mohamad Krayem * y , Philippe Aftimos y, Ahmad Najem , Tim van den Hooven , Adriënne van den Berg 3, Liesbeth Hovestad-Bijl 3, Rik de Wijn 3, Riet Hilhorst 3 , Rob Ruijtenbeek 3, Malak Sabbah 1, Joseph Kerger 2, Ahmad Awada 1,2 , Fabrice Journe 1 and Ghanem E. Ghanem 1 1 Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium; [email protected] (A.N.); [email protected] (M.S.); [email protected] (A.A.); [email protected] (F.J.); [email protected] (G.E.G.) 2 Medical Oncology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium; [email protected] (P.A.); [email protected] (J.K.) 3 PamGene International BV, 5211HH ’s-Hertogenbosch, The Netherlands; [email protected] (T.v.d.H.); [email protected] (A.v.d.B.); [email protected] (L.H.-B.); [email protected] (R.d.W.); [email protected] (R.H.); [email protected] (R.R.) * Correspondence: [email protected] Both authors equally contributed to this manuscript. y Received: 20 January 2020; Accepted: 20 February 2020; Published: 22 February 2020 Abstract: Mitogen-activated protein kinase (MAPK) inhibition with the combination of BRAF (Rapidly Accelerated Fibrosarcoma) and MEK (Mitogen-activated protein kinase kinase) inhibitors has become the standard of first-line therapy of metastatic melanoma harbouring BRAF V600 mutations. However, about half of the patients present with primary resistance while the remaining develop secondary resistance under prolonged treatment.
    [Show full text]